 Home > Active Ingredient News > Antitumor Therapy > Front Oncol: Palbociclib combined with letrozole in the first-line treatment of HR+ /HER2- predictors of primary drug resistance in metastatic breast cancer (MBC)

Front Oncol: Palbociclib combined with letrozole in the first-line treatment of HR+ /HER2- predictors of primary drug resistance in metastatic breast cancer (MBC)

 Last Update: 2021-11-12
 Source: Internet
 Author: User

Tags

advanced biotech

squamous lung cancer

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Hormone receptor (HR)+ , human epidermal growth factor 2 (HER2)-breast cancer (BC) is the most common breast cancer subgroup, accounting for 60-70% of all patients
.

Endocrine therapy (ET) is the standard treatment for these patients

Hormone receptor (HR)+ , human epidermal growth factor 2 (HER2)-breast cancer (BC) is the most common breast cancer subgroup, accounting for 60-70% of all patients

2016 Nian 1 month to 2020 Nian 12 during the month, 318 Li MBC patients received palbociclib joint letrozole as first-line therapy
.

Finally, 305 patients were included in the analysis

2016 Nian 1 month to 2020 Nian 12 during the month, 318 Li MBC patients received palbociclib joint letrozole as first-line therapy

The survival analysis of palbociclib combined with letrozole as the first - line treatment found that the median PFS of patients was 28.
7 months (95% CI: 22.
5-34.
9), and the median OS was not reached .

Compared with patients with weak ER positive, patients with strong ER positive had longer PFS (median PFS: 30.

Pathological factors affecting prognosis

Pathological factorsaffecting prognosis Pathological factors affecting prognosis

ECOG score (p = 0.
677), age (p = 0.
925) has nothing to do with PFS
.

Primary drug resistance refers to disease recurrence within 2 years of adjuvant ET treatment; secondary drug resistance is defined as disease recurrence within 2 years of adjuvant ET therapy or within 1 year after completion of adjuvant ET therapy

ECOG score (p = 0.

Clinical factors affecting prognosis

Clinical factors affecting prognosis Clinical factors affecting prognosis Clinical factorsaffecting prognosis clinical factors

Primary resistance to auxiliary ET (HR: 1.
91, 95% CI: 1.
13, 3.
24; p = 0.
022), liver metastasis (HR: 2.
17, 95% CI: 1.
42, 3.
31; p<0.
001), serum CA -15-3 level increased (HR: 1.
99, 95% CI: 1.
31, 3.
01; p = 0.
005), ER weakly positive (HR: 2.
28, 95% CI: 1.
20, 4.
33; p = 0.
024), Ki-67 3 + Or 4+ [HR: 2.
58 (95% CI: 1.
17, 5.
67) and 10.
28 (95% CI: 3.
52, 30.
09); p<0.
001) and BRCA2 mutation (hazard ratio: 9.
59, 95% CI: 3.
58, 25.
70) ;p<0.
001) is associated with PFS short
.

Primary resistance to auxiliary ET (HR: 1.

Multivariate analysis found that the primary drug resistance of adjuvant ET (HR=2.

PFS multi-factor analysis

PFS multivariate analysis PFS multivariate analysis

The results of logistic regression analysis of primary drug resistance factors suggest that primary drug resistance of auxiliary ET (OR: 1.

14, 95% CI: 0.
06, 2.
18; p = 0.

The results of logistic regression analysis of primary drug resistance factors suggest that primary drug resistance of auxiliary ET (OR: 1.
14, 95% CI: 0.
06, 2.
18; p = 0.
038), liver metastasis (OR: 1.
56, 95% CI: 0.
71 , 2.
42; p<0.
001), initial CA-15-3 increased (OR: 1.
51, 95% CI: 0.
63, 2.
49; p<0.
001), ER weak expression (OR: 2.
22, 95% CI: 0.
99, 3.
51; p<0.
001) and BRCA mutations (OR: 2.
85, 95% CI: 0.
75, 5.
31; p = 0.
010) affect PFS at 6 months
.

Logistic regression analysis of primary drug resistance factors

logistic regression analysis of primary drug resistance factors logistic regression analysis of primary drug resistance factors

In 38 is embodiment palbociclib primary resistance in patients in the United letrozole, 35 patients received second-line treatment
.
Capecitabine is the most commonly used treatment, followed by paclitaxel, everolimus combined with exemestane, fulvestrant and others
.
The 6-month disease control rate was 31.
4% (including capecitabine 31.
3%, paclitaxel 42.
9%, everolimus 40.
0%, and fulvestrant 50.
0%)
.
In 38 is embodiment palbociclib primary resistance in patients in the United letrozole, 35 patients received second-line treatment
.
Capecitabine is the most commonly used treatment, followed by paclitaxel, everolimus combined with exemestane, fulvestrant and others
.
Capecitabine is the most commonly used treatment, followed by paclitaxel, everolimus combined with exemestane, fulvestrant and others
.
The 6-month disease control rate was 31.
4% (including capecitabine 31.
3%, paclitaxel 42.
9%, everolimus 40.
0%, and fulvestrant 50.
0%)
.

Follow-up treatment plan after progression

Follow-up treatment plan after progression Follow-up treatment plan after progression

In summary, this study explored factors affecting palbociclib combined with letrozole as the first-line treatment for HR+ /HER2-MBC patients
.
Optimize treatment strategies for this type of patients in the future
.
In summary, the study explores the influence of the study explores the influence of the study explores the factors affecting palbociclib combined with letrozole as the first-line treatment of HR+ /HER2-MBC patients
.
Optimize treatment strategies for this type of patients in the future
.
Palbociclib combined with letrozole is used as a first-line treatment factor for HR+ /HER2-MBC patients
.
Optimize treatment strategies for this type of patients in the future
.

Original source:

Kim JY, Oh JM, Park YH, Ahn JS and Im YH (2021) Which Clinicopathologic Parameters Suggest Primary Resistance to Palbociclib in Combination With Letrozole as the First-Line Treatment for Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer? Front.
Oncol.
11:759150.
doi: 10.
3389/fonc.
2021.
759150 Kim JY, Oh JM, Park YH, Ahn JS and Im YH (2021) Which Clinicopathologic Parameters Suggest Primary Resistance to Palbociclib in Combination With Letrozole as the First-Line Treatment for Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer? Front.
Oncol.
11:759150.
doi: 10.
3389/fonc.
2021.
759150 Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.